US2012232259A1PendingUtilityA1

Compositions and methods for modulating lymphocyte activity

54
Assignee: MURPHY KENNETHPriority: Jun 20, 2002Filed: Apr 3, 2012Published: Sep 13, 2012
Est. expiryJun 20, 2022(expired)· nominal 20-yr term from priority
Inventors:Kenneth M. MurphyNorihiko WatanabeTheresa L. MurphyJianfei Yang
C07K 14/70521C07K 14/70532C07K 2319/30C07K 2319/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid having at least 99% nucleic acid sequence identity to a nucleic acid encoding a polypeptide having the amino acid sequence of SEQ ID NO:6. 
     
     
         2 . The nucleic acid of  claim 1 , wherein the polypeptide comprises an Ig domain and an ITIM domain.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.